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According to the data of the WHO, during the last 
30 years approximately 30% of the world’s popu-
lation survived without modern medicaments and 
appropriate medical service. Out of them, 47% of 
people are living in Africa, 65% in India, 29% in 
countries of the East Mediterranean and 26% in 
Southeast Asia. Countries with high income con-
sume up to 90% of all medicamentous remedies 
produced in the world [1]. Many dangerous infec-
tious diseases could be prevented with vaccination 
of infants under 1 year of age. Nevertheless, only 
75% of children are provided with obligatory vac-
cines, while 27 million of children born annually 
remain practically without vaccination [2]. 
Today the production of vaccines is becom-
ing more and more laborious and expensive, 
thus hindering global vaccination. In addi-
tion, a series of obscure questions still remain 
regarding prophylactic immunity. For instance, 
approximately 3 million newborns die annually 
regardless of whether they are vaccinated with 
parenteral vaccines [2]. 
Thanks to developments in the field of molec-
ular biotechnology and immunology during the 
last 10–15 years, new strategies are now being 
considered for the production of new-generation 
vaccines. In this regard, one innovative approach 
is the use of mucosal vaccines. 
The mucosa is the port of entry for many 
pathogens, in particular, bacteria and viruses 
that invade the host through respiratory, 
gastro intestinal or genital surfaces. The primary 
defense of these tissues is the mucosal immune 
system that can induce secretory IgA and serum 
IgG responses, thus providing two layers of 
defense against mucosal pathogens [3,4]. It has 
been estimated that the human mucosal surface 
sums up to 400 m2 [5], and that mucosal-asso-
ciated lymphoid tissue (MALT) contains 50% 
of total body immunity producing 70% of the 
body’s immunoglobulin as secretory IgA [6]. 
Administration of vaccines onto mucosal sur-
faces is more effective than parenteral administra-
tion at stimulating a mucosal immune response 
and can also elicit humoral, cell-mediated and 
systemic immune responses [7]. Mucosal deliv-
ery has the additional advantage of not needing 
syringe administration, making immunization 
practice more acceptable and decreasing the 
cost of an immunization program. Needle-free 
vaccinations increase the speed of vaccine deliv-
ery and are safer for both the patients and the 
healthcare staff. It has been calculated that 
3 million healthcare professionals are injured 
worldwide with needles infected with hepatitis 
B virus (HBV), hepatitis C virus (HCV) and 
HIV [8]. In addition, needle-free vaccinations 
eliminate the necessity of trained healthcare staff 
to deliver the vaccine [8]. Mucosal vaccines offer 
distinct advantages especially for en masse immu-
nization under epidemic and pandemic threats 
as well as threats of bio terrorism. However, 
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traditional vaccines are usually administered intramuscularly 
and subcutaneously since injection delivers a known quantity of 
vaccine and results in the production of antibodies and lymphoid 
cells that are measured in blood samples without difficulty [9]. 
On the contrary, it is difficult to measure the dose of a mucosally 
delivered vaccine that actually enters the body [10]. In addition, 
the majority of vaccines are not immunogenic when delivered 
mucosally and need the use of strong adjuvants, such as the chol-
era toxin and the heat-labile enterotoxin of Escherichia coli, or 
effective delivery systems [11]. 
Two features make mucosal vaccines attractive prophylactic 
instruments: first, the generation of both mucosal and systemic 
immunity; second, the most specific and easy penetration of 
many pathogens is across the mucous membrane. For example, 
it was shown that dendritic cells (DCs) of mucosal surfaces spe-
cifically catch virions of HIV from inner cavities and facilitate 
their entrance into M cells of Peyer’s patches as well as into inner 
submucous levels of lamina propria [12]. Therefore, the first line of 
defense can be raised at the initial step of interaction of pathogens 
with the mucosal membrane. 
Despite their advantages, up to now few vaccines approved for 
human use are mucosally delivered; examples are oral vaccines 
against poliovirus, rotavirus, Vibrio cholerae, Salmonella typhi and 
a nasal influenza vaccine [9,13]. 
One promising strategy for the production of mucosally deliv-
ered vaccines is the expression of candidate vaccine antigens in 
transgenic plant tissues. Subunit vaccines produced in plants 
would be safe and inexpensive to produce, and some of these 
plant-produced vaccines, such as MucoRice, were stable at room 
temperature for 3 years [14]. In this article, we will evaluate the 
advantages and disadvantages of using transgenic plants for the 
development of mucosal vaccines. In particular, we will explore 
the potential of vaccines produced in plant cells against widespread 
infectious diseases such as HIV, hepatitis B and TB. 
Mucosal delivery & immunity
The success of a mucosally delivered vaccine is based on activa-
tion of the mucosal immune system. This system is the primary 
defense of the mucous membrane lining the digestive, respiratory 
and urogenital tracts. These membrane surfaces are defended by a 
group of organized lymphoid tissue structures known commonly 
as MALT. MALT can be subdivided into sites such as the gut-
associated lymphoid tissue (GALT), the nasopharynx-associated 
lymphoid tissue and the bronchi-associated lymphoid tissue [8]. In 
the intestinal GALT, mucosal inductive sites include the Peyer’s 
patches, a large cluster of lymphoid follicles. The follicle-associ-
ated epithelium covering the Peyer’s patches contains specialized 
epithelial M cells that transport intact macromolecules and micro-
organisms across the epithelial barriers directly to subepithelial 
DCs that then present antigen in adjacent mucosal T-cell areas [9]. 
M cells are flattened, epithelial cells that lack the microvilli that 
characterize the rest of the mucous epithelium. M cells also have a 
deep invagination, or pocket, in the basolateral plasma membrane 
that contains T and B lymphocytes and DCs [4]. Intact antigens 
and microorganisms are transcytosed into the pocket and than 
transferred to the antigen-processing and -presenting cells for the 
initiation of mucosal IgA responses [4]. Following antigen process-
ing and presentation, IgA-committed B cells migrate to distant 
effector sites such as the lamina propria of the gut and respiratory 
tract. Dimeric IgA is secreted into secretions as secretory IgA that 
prevent the initial interaction of the pathogen with receptors on 
the mucosal cell surface [4]. Peyer’s patches are also populated by 
B cells that produce serum IgG. Thus, local IgG synthesis can also 
occur in the mucosal tissues following mucosal vaccination [8,15].
Vaccine administered mucosally may be partly degraded before 
reaching effector sites on the surface of the GI tracts [10], therefore, 
either a large amount of vaccine needs to be administrated or the 
purified antigen should be protected from proteolysis through 
encapsulation [10]. Transgenic plants that express an antigenic pro-
tein are a promising strategy to produce and mucosally deliver large 
doses of protective antigens in encapsulated forms, as the plant 
cell walls protect the antigen from the acidic environment of the 
stomach and enable intact antigen to reach the GALT [3,7,10]. Plant-
made mucosal vaccines have several advantages including their 
low cost of production, higher scale-up capacity, and easy storage 
and transport. Moreover, the production of plant-made mucosal 
vaccines could eliminate downstream processing of traditional 
vaccines such as purification, sterilization and refrigeration [16]. In 
addition, the production of vaccines in plants allows the introduc-
tion of post-translational modifications such as glycosy lation, lipid 
modifications and disulfide bond formation [17]. Plant-based vac-
cines do not have shortcomings that are intrinsic of other expres-
sion systems. For example, plant RNA viruses, unlike animal, 
come through the gastroenteric tract without entering cells of the 
mucosa. There are no prions or other morbific pathogens danger-
ous for human in plants. In addition, the use of agricultural plants 
for the production of mucosal vaccines (i.e., fruits, vegetables, cere-
als and greengrocery plants) in the majority of cases reduces the 
possibility of allergy and auto immune diseases. Mucosal vaccines 
based on fruits, leaves or seeds might be used as raw (uncooked) 
or dried material without the loss of immunogenic quality [18]. We 
have shown that transgenic tomato fruits containing antigenic pro-
teins p24 (HIV-1) and HBV surface antigen (HBsAg) persistently 
inherit these proteins in seven examined generations in amount 
of 19–25 µg/g of total soluble protein (TSP) [19]. 
Mucosal delivery of several plant-produced antigens has elic-
ited antigen-specific antibodies in mice and in humans. The 
list includes vaccines against cholera [20], rabies [21], Norwalk 
virus [22], diarrhea [23], hepatitis B [24] and others that are at the 
stage of preclinical and clinical trials on animals and humans [20]. 
Recent studies demonstrated that mice orally immunized with 
plant-derived vaccine generated both systemic and mucosal 
immune responses. By contrast, subcutaneously immunized mice 
developed only systemic immunity [25].
Plants used for the production of mucosal vaccines 
Several expression systems can be used for the production of anti-
gens in plants. Antigens can be expressed from transgenes stably 
integrated in the nuclear or plastid genome of transgenic plants, or 
from engineered plant viruses infected into the plant tissues [10]. The 
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decision is complicated by the fact that the plant production system 
can influence antigen content, stability, authentic conformation 
and cost of production [7]. Several plants have been used for the 
production of mucosal vaccines, including seed crops such as maize, 
soybean and rice. Expression and accumulation of antigens in seeds 
have several advantages such as high accumulation and stability 
of recombinant protein, and ease of purification. Recently, Nochi 
et al. expressed the cholera toxin B subunit (CTB) in rice seeds [25]. 
When mucosally fed, antigens from transgenic rice seeds were taken 
up by the M cells covering the Peyer’s patches and induced CTB-
specific serum IgG and mucosal IgA antibodies with neutralizing 
activity [25]. In addition, the rice-expressed CTB remained stable 
and maintained immunogenicity at room temperature for greater 
than 1.5 years and was protected from pepsin digestion in vitro 
[25]. Another possibility could be the use of transgenic single-cell 
cultures, such as the tobacco plant cell lines BY2 and NT1. These 
systems offer the advantages of high-level containment and the 
possibility of producing recombinant proteins in bioreactors so that 
good laboratory and manufacturing practices are easily applied. In 
addition, these lines have low alkaloid content so that they can be 
used for mucosal delivery [7,26]. Other plants used for the production 
of plant-based vaccines include tobacco, potato, lettuce, spinach, 
tomato, carrot, pea, alfalfa, soybean and other plants [18].
One challenge in mucosal vaccine design is that a 1000-fold 
higher level of vaccine needs to be administered mucosally com-
pared with by injections [9,10]. However, up till now, the majority 
of plant-derived pharmaceuticals have been produced by nuclear 
transformation and stably integrated nuclear transgenes usually 
yield low levels of expression (0.01–0.4% of the TSP) since sites of 
integration into host DNA vary among transformed lines, expressed 
sequences can be subjected to gene silencing, and the foreign pro-
teins are sometimes degraded in plant tissues [27,28]. A promising 
alternative for the expression of mucosal antigens is the production 
of recombinant proteins in transformed chloroplasts. Plastids have 
the potential to accumulate enormous amounts of recombinant 
proteins because of the high copy number (~10,000 copies) of the 
chloroplast genome in each plant cell. Oey et al. reported that a 
phage-derived lytic protein could be expressed to more than 70% of 
a plant’s TSP [29]. Chloroplast transformation offers several advan-
tages over nuclear transformation, including uniform transgene 
expression rates, no gene silencing and transgene containment. The 
chloroplast stroma also allows post-translational modification such 
as oligomerization and disulfide bond formation [28]. Plastid trans-
formation combines characteristics of prokaryotic and eukaryotic 
expression systems and, therefore, can be a suitable platform for 
the expression of viral and bacterial antigens such as human papil-
lomavirus (HPV)-16 L1 and CTB [16,30,31]. Another advantage of 
chloroplast transformation for the production of mucosal vaccines 
is that multigenic engineering is possible, providing the opportunity 
to coexpress antigens and adjuvants in plastids [16]. Since the first 
vaccine produced in transgenic plastids [30], a number of antigenic 
proteins have been expressed via chloroplast genetic engineering 
and several chloroplast-derived, mucosally delivered vaccines could 
induce an appropriate antigen-specific immune response and con-
fer protection against pathogens [20]. Mucosal immunization with 
transplastomic plant material containing the plague fusion antigen 
F1-V without adjuvant conferred greater protection (88%) against a 
50-fold lethal dose of aerosolized Yersinia pestis than subcutaneous 
immunization (33%) [25,32]. 
One disadvantage of using chloroplast transformation is that, 
up till now, the majority of the antigens produced in transplas-
tomic plants have been produced in tobacco, which is not edible 
and unsuitable for oral delivery. However, recently the HIV anti-
gens p24 and Nef have been expressed in plastids of tomato [33]. 
Although green tomatoes accumulated the HIV antigens to 
approximately 2.5% of the TSP, there was no expression in ripe 
red fruits [33]. The authors speculated that this was because ripe 
red tomatoes contain chromoplasts that are generally less active 
in plastid gene expression than chloroplasts.
Several therapeutic proteins and antigens against anthrax, 
cholera, malaria and autoantigen for diabetes were produced in 
lettuce chloroplasts [20]. Davoodi-Semiromi et al. reported the 
expression of CTB fused to two malarial vaccine antigens apical 
membrane antigen 1 (AMA1) and merozoite surface protein1 
(MSP1) in tobacco and lettuce plastids [20,25]. CTB–AMA1 and 
CTB–MSP1 accumulated as up to 13.17% of the TSP in tobacco 
and up to 7.3 and 6.1% of the TSP in lettuce, correspondingly. 
Mucosal immunization of Balb/C mice orally with tobacco trans-
plastomic leaves conferred 100% protection against cholera toxin 
challenge and inhibited proliferation of the malarial parasite [25]. 
Tomato as a production system
In the last 10 years, along with other systems, tomato plants have 
often been used for the production of plant-based vaccines and sev-
eral investigators have considered tomatoes as a good option for bio-
pharming [22,34,35]. Tomato are one of the most consumed vegetables 
in the world. Annually the consumption of tomato is estimated at 
the sum of US$15 billion. Tomato fruits can be consumed as raw, 
cooked material, in the form of pastes, juices and ketchups. One of 
the most famous compounds in tomatoes, lycopene, is not destroyed 
with drying or cooking. At the same time, tomato is an unpreten-
tious plant and its growth is possible everywhere in the world, in 
open and close environments. Fruits can be consumed both fully 
matured and at greenish or yellowish ripening stages. Therefore, 
using tomato fruits as edible vaccines does not require antigen puri-
fication before vaccine delivery. In addition, tomatoes contain many 
natural, valuable compounds such as lycopene, which has antitumor 
activity [36], and natural steroid alkaloides (e.g., saponin esculeoside, 
a-tomatine and its derivatives dehydrotomatine and tomatidine that 
possess antimicrobial, fungicidal and anti-inflammatory features, 
and antitumor activity [37–39]).
It is of value that tomato contains the natural adjuvant a-toma-
tine [33]. O-b-d-xylopyranosyl-(1→3)-(O-b-d-glycopyranosyl 
-[1→2]-O-b-d-glycopyranosyl-[1→4]-O-b-d-glycopyranosyl-
[1→4])-O-b-d-glycopyranosyl-tomatidine is a natural nontoxic 
adjuvant whose content can reach up to 0.5 mg/g of fresh weight 
in green fruits or, after drying, 1–34 mg/g of dry weight [37]. 
Tomato plants have high regeneration capacity. Isolated coty-
ledons of 10–14 days old seedlings have high organogenic and 
embryogenic activities. Placing explants onto murashide media 
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containing phytohormones (i.e., indole-3-acetic acid [IAA] 
and cytokinins) leads to callus formation followed by shoot 
regeneration and rhizogenesis. 
Tomato seedlings can be genetically transformed using different 
techniques. They can be transformed by inoculation of explants 
with a suspension of agrobacterial cells and by agroinfection of 
cotyledons, apexes, leaves, ovaries and whole fruits. It is also pos-
sible to obtain regenerants using the flamingo bill methods [40]. 
Normal fruits with fully developed seeds were obtained after 
agroinfection of receptacle or ovaries that gave transgenic plants 
of T1 generation after selection on kanamycin 100 mg/l. In our 
work, green fruits infected directly with agrobacterial culture 
were transformed with the genes T- and B-cell epitope-containing 
immunogenes (TBI)–HBS (HIV-1) and PreS2-S (HBV). The pres-
ence of the transgenes in transgenic lines was detected by PCR, 
and Southern and northern blot analyses performed on DNA (or 
reverse transcriptase-PCR products) isolated from pericarp tissues. 
The presence of the antigenic proteins was analyzed by ELISA [41]. 
Zhang et al. compared the use of potato and tomato for the 
production of mucosal vaccines against Norwalk virus [22]. They 
came to the conclusion that tomato plants were more suitable 
for the creation of mucosal vaccines and that dried tomato fruits 
were more effective than dried potato tubers. According to these 
data, the tomato-based vaccine was ten times more immunogenic 
than the vaccine based on potato tubers due to the presence of 
tomatine. Zhang et al. speculated that the antigenic proteins were 
more stable in tissues of tomato fruits in comparison to potato 
tubers, probably owing to the presence of more effective inhibitors 
of proteases in tomato [22].
In some cases the use of the genes such as those from HIV [42], 
HBV [43], HPV [44], hepatitis E virus [45] and SARS [46] resulted 
in difficulties of growth and development of plants.
We considered that the production of transgenic plants could be 
improved if the gene ugt from corn, which encodes the synthesis 
of uridine–diphosphate–glucose-transferase, or by its trivial name, 
IAA–glucose synthase, was introduced [47]. The product of the 
expression of this gene catalyzes the binding of the phytohormone 
IAA into a conjugate form with glucose, thus providing a pool of 
bound IAA. Later, free IAA can be liberated and act as a growth 
activator in the proper tissue at the proper time [48]. In our work, 
after the introduction of the gene ugt, we received well developed 
tomato plants transformed with the gene TBI–HBS with abundant 
harvest up to four to five times [47].
Plant-produced mucosal vaccines against widespread 
infectious diseases
Trials to create mucosal plant-based vaccines against HIV were 
carried out at different times using the envelope gene env [49], trans-
membrane protein gp41 [50], genes of core proteins p17/p24 [51], as 
well as regulatory proteins of early events of replication Tat and 
Nef [52,53]. Antigenic dominants of these proteins synthesized in 
plants were able to induce immune responses in mice.
Scotti et al. investigated the possibility of expressing the protein 
Pr55GaG HIV-1, a protein that usually accumulates at low levels 
in nuclear-transformed plants, using plastid transformation [54]. In 
transplastomic plants the level of Pr55GaG expression increased 
up to 7–8% of the TSP after the fusion with RbcL, and the pro-
tein Pr55Gag formed virus-like particles (VLP) similar to VLPs 
from the baculovirus expression system.
Meyers et al. compared the expression of HIV-1 Pr55Gag, a 
truncated Gag (p17/p24) and the p24 capsid subunit using trans-
genic plants and transient expression via Agrobacterium tume-
faciens and recombinant tobamovirus vectors, respectively [51]. 
Expression of Pr55Gag was low in all systems; however, the 
Agrobacterium-mediated transient expression of p24 and p17/p24 
yielded more than 1 mg p24 per kg of fresh weight of tobacco 
leaves. In addition, chloroplast targeted protein levels were highest 
in transient and transgenic expression. The transiently expressed 
protein p17/p24 was not immunogenic in mice, however, it was 
able to boost both humoral and T-cell responses induced by the 
administration of the DNA vaccine pTHGaGC [51].
Lombardi et al. studied the possibility of using the protein 
negative regulatory factor (NEF) HIV-1, which participates in 
early stages of HIV infection, as a potential vaccine [55]. The 
accumulation of NEF is usually low in plants after stable nuclear 
transformation. NEF HIV-1 was expressed using agrobacterial 
coinfiltration together with well-known proteins with silencing 
suppressor activity (p25 potato virus X [PVX], p19AMCV and 
p19TBSV). p19AMCV was more effective as an inhibitor of 
silencing and its coinfiltration resulted in a threefold increase of 
NEF HIV-1 expression (up to 1.35% of the TSP).
In another study, the protein NEF fused with p24 HIV-1 
accumulated up to 40% of the TSP in plastids of tobacco and 
tomato [33].
Production of binary candidate vaccine against HIV-1 & 
HBV simultaneously based on transgenic tomato
It should be mentioned that HIV weakens the human immune 
system and is usually accompanied by other diseases that can 
cause the death of the patient. For example, AIDS often appears 
as an associated infection with hepatitis B and TB. Therefore, it 
is rational to perform the prophylaxis against HIV together with 
the prophylaxis against HBV. Hence, we tried to create a binary 
vaccine simultaneously against HIV-1 and HBV based on the 
chimeric gene TBI–HBS. 
It was shown  that genes encoding proteins of HIV have homol-
ogous sites with approximately 15,000 human genes such as those 
encoding interferon receptors, receptors of macrophages, colony-
stimulating factors, mast cells, growth factors of the eye lens, 
fibroblast growth factor receptors and many others [56]. Therefore, 
for the creation of the chimeric gene TBI, Eroshkin et al. used 
polyepitopic immunogenes containing fragments of viral pro-
teins that were not found in human proteins (auto immunogenic 
epitopes) [57]. There were five potential B-cell epitopes and four 
epitopes stimulating T-helper (Th)-cell responses in the artificial 
poly epitopic protein TBI. Six neutralizing epitopes were taken 
from the envelope protein Env (HIV) and three epitopes from the 
core protein encoded by the gene gag. The sequences of epitopes 
used were reflected in the name of the artificial gene TBI able to 
stimulate the synthesis of neutralizing antibodies. The sequence of 
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the main neutralizing epitope of the Env protein, IQRGPGRAF, 
was also introduced into the polyepitope TBI [57]. In addition, a 
sequence encoding 226 amino acids of HBsAg, the main anti-
genic protein of HBV envelope, was introduced in the synthetic 
gene TBI–HBS. As a result, the construct TBI–HBsAg encoded 
for HIV and HBV epitopes and the activation of immunity 
against associated infections with HIV and HBV was obtained.
During the years 2002–2009, we studied the expression of the 
synthetic gene TBI–HBS and PreS2-S in transgenic tomato plants, 
with the same team. In the frame of this work, fresh, lyophilized 
and incapsulated vaccines were obtained (Figure 1). Results of these 
investigations were described in a series of publications [19,58–63] in 
which it was demonstrated that the genes TBI–HBS and PreS2-S 
were able to induce the synthesis of antigenic proteins in tomato 
fruits that were used as candidate vaccines in animal trials. These 
trials have shown that the mucosal vaccine produced in transgenic 
tomato was able to induce in mice both mucosal and systemic 
responses after feeding with lyophilized fruits [59–62].
As mentioned previously, the synthesis of the antigens produced 
in transgenic tomato plants transformed with the gene TBI–HBS 
was stable for seven generations (and perhaps longer, but experiments 
were not done) [19].
In addition we investigated how long the antibodies raised 
against TBI–HBS were present in mice during their lives. We 
determined that during 9–11 months after vaccination the level of 
antibodies, measured as amount of anti-HBsAg, was high enough. 
There was a decrease in antibodies to the level of the control 
after 19 months. It should be mentioned that the life expectancy 
of mice is approximately 2 years. Thus, mice maintained the 
immune response practically half of their lives after vaccination 
with the tomato-based vaccine [63].
Mucosal vaccine against TB
Annually, TB causes nearly 2 million human deaths worldwide, 
mostly in developing countries, and currently almost 2 billion 
individuals are infected with Mycobacterium tuberculosis [13,64]. TB 
is also a leading cause of death among HIV-infected individuals, 
with coinfection accounting for up to a third of deaths associ-
ated with AIDS [64]. Mycobacterium bovis is the cause of animal 
TB that can affect animals in the wild or in captivity, and is 
responsible for approximately 6% of total deaths through zoo-
nosis [64]. Most of the world’s population is vaccinated with the 
only approved TB vaccine: bacillus Calmette–Guérin (BCG), an 
attenuated vaccine derived from M. bovis. BCG vaccination pro-
tects against childhood forms of TB, but efficacy in adults against 
pulmonary TB ranges from 0 to 80% in different trials [13,64]. 
The induction of a mucosal immune response is important for 
protection against diseases for which entry and pathogenesis are 
clearly related to the mucosal system. Since the mucosal surfaces 
of the lung are normally the organ in which TB infection is initi-
ated and is the major site of pathology, an immune response in 
the lung could play a major role in restricting initial infection 
and colonization of M. tuberculosis and M. bovis. However, the 
parenteral route of immunization, which is normally used for vac-
cination with the BCG vaccine, does not elicit optimal immune 
responses in the lung. 
Since mucosal delivery can induce a common mucosal immune 
response, mucosal immunity in the respiratory tract can be stimu-
lated by oral administration of an appropriate antigen. Needle-
free vaccine administration also has the advantages of being safer 
and of eliminating problem of infections transmitted through the 
repeated re-use of needles. This last point is particularly important 
considering the high rate of HIV–TB coinfection in developing 
countries [65]. 
The protein antigen 85 complex B (Ag85B) and early secreted 
antigen target 6 kDa (ESAT-6) are two of the major antigens 
produced by M. tuberculosis during infections and are both 
capable of inducing strong immune responses in a number of 
animal models [11]. Zelada et al. demonstrated the expression 
of the ESAT-6 protein in Nicotiana tabacum leaves using a vec-
tor based on PVX [66]. The ESAT-6 open reading frame was 
expressed as a fusion protein with the 2A catalytic peptide of 
foot-and-mouth disease virus and the amino terminal of the coat 
protein (CP) of PVX. The PVX-based vectors produced virions 
A B C
Figure 1. Tomato-based binary vaccine against HIV and hepatitis B. (A) Fresh vaccine, (B) lyophilized vaccine and
(C) incapsulated vaccine. 
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with a chimeric capsid composed of the fusion ESAT-6–2A-CP 
and native PVX CP. Yields of ESAT-6–2A-CP fusion in agro-
infiltrated tobacco leaves ranged from 0.5 to 1% of the TSP [11]. 
A system based on transient replication of plant virus vectors was 
also used by Dorokhov et al. [67] for the expression of the antigens 
Ag85B, ESAT-6 or Ag85B–ESAT-6 fusion in plant leaves. The 
technology used by Dorokhov et al. comprised the construction 
of tobacco mosaic virus-based vectors with the CP genes sub-
stituted by those for TB antigens [67], the delivery to Nicotiana 
benthamiana leaves of binary vectors containing a cDNA copy of 
the vector virus genome by agroinjection, and the coexpression of 
a protein suppressor of virus-induced gene silencing (P19) with 
the virus vectors [68]. This technology allowed the production of 
a very high level of the TB antigens in plants cells; particularly 
the level of Ag85B accumulation ranged up to approximately 
800 mg/kg of fresh leaves [68]. 
Recently, Floss et al. reported the expression of the Ag85B and 
ESAT-6 antigens as an elastin-like peptide (ELP) fusion in trans-
genic tobacco plants [69]. Mice and piglets were injected with 
the fusion protein TBAg–ELP purified using inverse transition 
cycling or with crude tobacco leaf extract, respectively. Antibodies 
recognizing the TB antigens were produced in mice and piglets. 
In addition, in mice a T-cell immune response able to recognize 
the native TB antigens was detected [69].
Rigano et al. investigated the ability of transgenic Arabidopsis 
thaliana plants to produce a fusion protein consisting of the 
B subunit of the Escherichia coli heat-labile enterotoxin (LTB) 
and ESAT-6 for the development of a mucosally delivered and 
targeted TB vaccine [65]. Both components of the fusion protein 
retained native antigenicity and the ability to form pentamers. 
The levels of LTB–ESAT-6 production in plants varied between 
11 and 24.5 µg/g fresh weight. A food-processing technique was 
used on transgenic tissues to standardize the antigen concentra-
tion in plant material and elongate shelf life. Arabidopsis material 
was pooled and freeze-dried. The pooling of processed Arabidopsis 
samples provided a batch of plant material with sevenfold con-
centrated, antigenically active fusion protein of uniform con-
centration [65]. To determine the ability of mucosal vaccination 
to generate immune responses, mice were fed with the freeze-
dried transgenic A. thaliana material [68]. The plant-synthesized 
LTB/ESAT-6 fusion protein induced antigen-specific responses 
from CD4+ cells and increased IFN-g production and, therefore, 
induced a Th1 response in the mesenteric lymph nodes. In addi-
tion, mice fed the transgenic material generated a type 2 response 
in the Peyer’s patch. Thus, the plant-derived TB antigen was deliv-
ered to the GALT and was able to prime an antigen-specific Th1 
response [68]. 
Recently, Matvieieva et al. produced transgenic lettuce plants 
(Lactuca sativa L.) with genes coding the synthesis of the TB 
antigens ESAT-6 and Ag85B [70]. Lettuce was chosen because this 
plant grows quickly and does not require any thermal treatment 
before its consumption [70]. As an alternative, carrot transforma-
tion was used for the production of a mucosal vaccine. Ling-Jian 
et al. reported the expression of the M. tuberculosis MPT64 protein 
in transgenic carrots [71]. 
Expert commentary
Methods of increasing the immunogenicity of mucosally 
delivered vaccines 
There are several issues regarding the mucosal delivery of subunit 
vaccines, such as degradation of the antigens by digestive enzymes, 
inefficient transport from the gut lumen to the GALT and induc-
tion of systemic immune tolerance [72]. In addition, mucosally 
administered subunit vaccines that consist of soluble, nonparticu-
late antigens have inherently low immunogenicity and can induce 
immune tolerance [9]. Mucosal vaccines can be more effective if 
they are multimeric and/or particulate. Viral structural proteins can 
self-assemble into organized macro molecular particulate structures 
called VLPs [72]. VLPs are promising mucosal vaccines because 
their size is appropriate for uptake by M cells and DCs, they can 
activate an innate immune response, and their structures mimic the 
form of an authentic virus [9]. Antigens of different origins form-
ing VLP were produced in plants and were shown to assemble into 
VLPs [73]. Fernández-San Millán et al. reported the expression of 
the major structural protein of the HPV-16 capsid, L1, in tobacco 
chloroplasts [31]. In plants, a very high expression level of the protein 
L1 was achieved (24% of  the TSP). The chloroplast-derived L1 
protein self-assembled into VLPs that were highly immunogenic 
in mice after intraperitoneal injections inducing a specific humoral 
response [31]. Norwalk virus capsid protein was expressed as VLP 
in tobacco, potato and tomato fruits, and the VLP produced in 
potato and delivered orally stimulated serum IgG and IgA responses 
in humans [72]. 
Codelivery with an adjuvant or targeting protein can also increase 
the ability of the mucosal immune system to recognize plant-derived 
antigens. Two such carrier molecules for subunit vaccines are the 
heat-labile toxin of enterotoxigenic E. coli (LT) and the cholera toxin 
of V. cholerae, two toxins recognized as very potent mucosal adju-
vants [7]. LT and cholera toxin consist of nontoxic B subunits and 
enzymatically active A subunits. Conjugation with LTB and CTB 
may facilitate antigen delivery and presentation to the GALT owing 
to their affinity to the GM1 gangliosides found on the surface of 
mucosal epithelial cells [7]. Several studies report the use of LTB and 
CTB as carrier proteins in plant-derived vaccines [7,68]. For instance, 
Zhang et al. recently produced transgenic rice seeds expressing the 
Chlamydophila psittaci antigen (MOMP) fused to LTB [74]. Oral 
immunization of mice with the rice material was able to induce 
mucosal and systemic immune responses [74]. 
Cholera toxin B subunit is also an efficient mucosal carrier mol-
ecule for the induction of oral tolerance to antigens and allergens [75]. 
Takagi et al. expressed in rice seeds T-cell epitopes derived from 
major Japanese cedar pollen allergens Cry j 1 and Cry j 2 fused 
with CTB or rice glutelin as a control [75]. Feeding mice with the 
transgenic material suppressed allergen-specific IgE responses and 
allergic symptoms at 50-fold lower doses of T-cell epitopes than 
required when using control seed [75]. 
The use of natural adjuvant can be very important in vaccine 
formulation. Morrow et al. demonstrated that the usage of tomatine 
highly increased the immune response against malaria, the pathogen 
Francisella tularensis and experimental tumors [39]. They showed that 
tomatine affected events occurring at the level of antigen-specific 
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receptors CD8, CD80 and CD86, increased the level of interferon 
and the activity of cytotoxic T lymphocytes, and blocked the infec-
tion of erythrocytes by Plasmodium malaria. It is obvious that the 
potential ability of tomatine should be studied urgently since it 
allows to combine soluble, subunit, plant-based vaccines with this 
accessible and inexpensive natural adjuvant.
Another challenge in the design of a mucosal vaccine is that it is 
impossible to determine exactly what dose of the vaccine actually 
crosses the mucosa, so a larger dose of vaccine is usually required. 
Future investigations should focus on the improvement of diag-
nostic methods of antigenic proteins, since a part of the antigens 
is inevitably lost in the GI tract. In addition, plants can modify a 
recombinant protein so that the immunoassay used cannot estimate 
correctly the quantity of the antigens. One well-known example is 
the production of lactoferrin in tobacco plant cells; in this case, lac-
toferrin was present in a modified form but its activity was increased 
up to 1000-times [76]. 
Downstream processing
To standardize and concentrate the vaccine in plant material it is 
possible to apply food-processing techniques to transgenic plant tis-
sues. Freeze-drying is a simple and inexpensive technique that can 
provide antigen stability at ambient temperature. This technique has 
also been applied to tomato-made vaccines [62,72,77]. 
Zhang et al. expressed the recombinant Norwalk virus capsid pro-
tein in tomato and potato using a plant-optimized gene and tested 
the immunogenicity of dried tomato fruit and potato tuber fed to 
mice [22]. The authors demonstrated that recombinant Norwalk 
virus in tomato fruit is a more potent immunogen than potato. In 
the same paper, the authors demonstrated that air-dried tomato 
fruit stimulated a stronger immune response than freeze-dried fruit, 
perhaps because air-drying limits the destruction of plant cell matrix 
and membrane systems that can occur with freeze-drying [22]. 
In our experience, lyophilized material is the most acceptable 
method for vaccine delivery. It should be mentioned that green and 
red tomatoes could differ in the content of antigenic protein. For 
example, the content of antigenic protein HBsAg (HBV) was high 
in green and yellowish tomato fruits, but the level of HBsAg severely 
decreased in mature red fruits. In addition, the content of tomatine 
is up to 10,000-times higher in green tomato fruits than in red 
tomato fruits [37].
Another issue to consider regarding delivery approaches is the 
correlation between immune response and antigen purity as some 
plant cell components may interfere with the performance of 
recombinant antigens. In this regard, Portocarrero et al. examined 
the antibody response induced in mice immunized intramuscu-
larly or intranasally with a plant-derived pB5 smallpox subunit 
vaccine administered with or without plant TSP [78]. The authors 
demonstrated that increasing the amount of TSP inhibited the 
pB5-specific response in the immunized mice and that intranasal 
administration was more sensitive to the presence of TSP contami-
nants than parenteral immunization. In addition, the recombinant 
smallpox vaccine administered intranasally required a larger dose 
of antigen to induce an antibody response comparable with that 
obtained by parenteral immunization. Finally, the plant-derived 
B5 administered to mucosal surfaces induced specific IgG and 
IgA responses, while intramuscular immunization produced only 
high serum IgG titers [78]. 
Based on the presented results, mucosal vaccines could be for-
mulated as lyophilized, green or ripening tomato fruits. Another 
possibility could be the delivery of vaccines as lyophilized extracts 
prepared from freeze-dried tomato fruits. Freeze-dried tomato 
fruits can be stored for a long time without the access of moisture 
and air, and without any loss of antigenic proteins. In our work, 
there was no significant loss of antigenic proteins in samples of 
freeze-dried tomato fruits upon 2 years storage at room temperature 
[Salyaev RK & Rekoslavskaya NI, Unpublished Data].
Five-year view
The plant-made vaccine of the future has to have the same efficacy 
and safety of other pharmaceuticals produced by other sources [7]. 
For these reasons, it is likely that the future plant-produced vaccine 
product will be processed and purified plant material and will not be 
delivered in fresh form. Probably, the plant material will not need to 
be extensively purified but more likely simple and inexpensive food 
processing techniques, such as freeze-drying, will be applied [15,63,79]. 
For effective protection from proteases of the gastric juices, vaccine 
might be encapsulated by using gastric-soluble material. 
Transgenic plants are very useful to produce and orally deliver 
vaccine antigens. However, technical problems, insufficient fund-
ing and the lack of commercial interest to conventional vaccines 
have slowed down the advancement of this technology [17,68]. 
Therefore, it will be of importance to continue the effective 
develop ment of mucosal vaccines and, in particular, their clinical 
trials for widespread use in medical practice. 
Another issue hindering the use of plant-made vaccines is the 
public confusion about genetically modified plants. In this regard, 
new methods to produce marker-free transgenic plants should be 
developed [33]. In this regard, it will be quite reasonable to not use 
marker and selective genes, but instead to apply molecular diag-
nostic techniques and in the case of success to clone transgenic 
plants obtained. 
Despite these concerns, in 2006 the world’s first plant-made 
vaccine candidate for Newcastle disease in chickens, produced 
in a suspension-cultured tobacco cell line by Dow Agro Science 
(IN, USA), was registered and approved by the US Department 
of Agriculture (USDA). In addition, two plant-made pharma-
ceuticals are moving through Phase II and Phase III human clini-
cal trials. Biolex’s (NC, USA) product candidate, Locteron®, is 
in Phase IIb clinical testing for the treatment of chronic hep-
atitis CA [101] and a Phase III clinical trial was recently com-
pleted with Protalix’s (Carmiel, Israel) product UPLYSO, a plant 
cell expressed recombinant glucocerebrosidase enzyme to cure 
Gaucher’s disease [17,102]. 
Recently, two new-generation vaccines were developed against 
HIV-1 and were used in clinical trials. One clinical trial (Vaxgen 
[CA, USA]) was performed with a vaccine based on the p120 
subunit (HIV-1); the vaccine was able to induce a real immune 
response and binding of virions with neutralizing antibodies but 
did not induced a broad immune reactivity. The second trial was 
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performed with a vaccine based on a recombinant adenovirus 
vector (rAd5) expressing Gag, Pol and Nef of HIV-1 (Merck 
[NJ, USA]). During the trial conducted by Merck and the US 
NIH, the recombinant adenovirus interacted with pre-existing 
adenoviruses and helped the entrance of HIV virions in tested 
African volunteers tested [80]. This raised numerous debates and 
doubts regarding the possibility of creating new-generation vac-
cines against HIV-1. It was said that the failures in vaccine design 
were provoked by insufficient knowledge of the nature of HIV-1 
and of the interaction of the virus with immune cells.
Later, a team of Russian scientists designed a new generation 
HIV vaccine based on 86 different epitopes of HIV to induce 
the synthesis of broad-spectrum neutralizing antibodies against 
HIV [81]. These sequences were carefully selected after compari-
son with well-known sequences in the human genome. Many 
epitopes were considered for the creation of synthetic (chimeric) 
sequences of the TCI (T- and C-cell immunogens) protein that 
were able to neutralize mutated and escaped 
virions. Up untill now, studies investigating 
the use of this chimeric gene for the creation 
of mucosal vaccine have not been performed.
Recently, several investigations are focus-
ing on the interaction of HIV with other 
associated viruses. Hepatitis B and C viruses, 
papillomavirus and Kaposi’s sarcoma virus 
have many similar features [82]; one of them 
is the ability to spread via sexual contact and 
to invade the host via the mucosal surface 
route. Therefore, it could be possible to cre-
ate multicomponent vaccines against three 
viruses by using immunogenic epitopes of 
HIV-1 (gp120 or chimeric poly epi topic gene 
T-cell immunogen), antigenic protein PreS2-S HBV and HPV L1. 
It may be assumed that using three immunogenic proteins could 
induce broad-spectrum neutralizing antibodies. For example, 
using the Forest Semliki virus for the expression of gp140 HIV-1 
resulted in significant increases in the synthesis of neutralizing 
antibodies against HIV-1 [83].
The hope is that all the successful results obtained in the last 
few years in these fields will also increase the interest towards the 
production of mucosal vaccines in transgenic plants.
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Key issues
• Mucosal vaccination is a perspective for the control of infectious diseases, since it is 
capable of inducing humoral and cell-mediated responses. 
• Transgenic plants can be used as bioreactors for the production of subunit, mucosally 
delivered protective antigens, as the plant cell walls protect the antigen from the acidic 
environment of the stomach and enable intact antigen to reach the gut-associated 
lymphoid tissue. In the case of encapsulated vaccines, capsules should be prepared 
from material that protects the antigen from the adverse conditions of the GI tract.
• Several expression systems can be used for the production of antigens in plants. 
• Transgenic plants are very useful to produce mucosal vaccines against widespread 
infectious diseases such as TB, hepatitis B and HIV.
• Technical problems hindering the development of this technology, such as increasing 
the immunogenicity of plant-made delivered vaccines and downstream processing, are 
now being resolved.
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